Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 215

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 215
---
 Stock on the satisfaction
of certain conditions. The Company has no guarantee that the conditions will be satisfied to require the purchase of all, or any additional
amount, of the ELOC funds. On February 5, 2025, the Company entered into the SPA, with participation from a member of the Company’s
Board and a single institutional investor, for the purchase and sale of (i) 127,551 shares of our common stock or common stock equivalents
in lieu thereof; and (ii) February 2025 Common Warrants to purchase up to 127,551 shares of common stock, at a combined public offering
price of $39.20 per share and warrant. In connection with this offering, the Company received net proceeds of approximately $4.2 million.
Additionally, during the six months ended June 30, 2025, the Company received net proceeds from the exercise of the remaining Series A
Preferred Warrants, the collection of subscriptions receivable and ELOC fundings of approximately $2.9 million. Furthermore, during the
six months ended June 30, 2025, we received net proceeds from the sales of Series D Preferred Stock of $2.2 million. Any estimate as to
how long the Company expects the net proceeds from the ELOC and Series D Preferred Stock funding may fund the Company’s operations
is based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than its current
expectations. Changing circumstances, some of which may be beyond the Company’s control, could result in less cash and cash equivalents
available to fund operations or cause the Company to consume capital significantly faster than currently anticipated, and the Company
may need to seek additional funds from additional sources sooner than planned.

37

Because
of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drug products,
the Company is unable to estimate the exact amount of its operating capital requirements. The Company’s future funding requirements
will depend on many factors, including, but not limited to those listed under “Factors Affecting Our Performance” above.

Identifying
potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process
that takes many years to complete, and the Company may never generate the necessary data or results required to obtain marketing approval
and achieve product sales. In addition, the Company’s product candidates, if approved, may not achieve commercial success. Commercial
revenues, if any, will be